AIM ImmunoTech (AIM) Share-based Compensation (2010 - 2025)
AIM ImmunoTech's (AIM) quarterly Share-based Compensation came in at -$100.0 in Q4 2025, up 99.9% YoY from -$50.03 in Q4 2024, and down 100.17% on a QoQ basis from $60000.0 in Q1 2025.
AIM ImmunoTech (AIM) Share-based Compensation (2010 - 2025) Analysis & Trends
AIM ImmunoTech (AIM) has 16 years of Share-based Compensation data on file, last reported at -$100.0 in Q4 2025.
- Quarterly Share-based Compensation rose 99.9% year-over-year to -$100.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $59900.0 (down 51.46% YoY) and the FY2025 annual result came in at $59900.0, down 84.77% from the prior year.
- Share-based Compensation retreated to -$100.0 in Q4 2025, from $60000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $526000.0 in Q1 2021 to a low of -$1.3 million in Q4 2021.
- A 5-year average of $88816.7 and a median of $82500.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 112.81% — and 2024, when it plunged 258.36%.
- Tracing AIM's Share-based Compensation over 5 years: stood at -$1.3 million in 2021, then jumped by 112.81% to $162000.0 in 2022, then slumped by 62.35% to $61000.0 in 2023, then sank by 258.36% to -$96600.0 in 2024, then soared by 99.9% to -$100.0 in 2025.
- The last three Share-based Compensation figures came in at -$100.0 (Q4 2025), $60000.0 (Q1 2025), and -$96600.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | - |
| 10 | AIM ImmunoTech | 4.42 Mn | -5.54 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -100.00 |
| Dec 31, 2025 | -100.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | -96,600.00 |
| Dec 31, 2024 | -96,600.00 |
| Sep 30, 2024 | 53,400.00 |
| Sep 30, 2024 | 53,400.00 |
| Jun 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | 35,000.00 |
| Sep 30, 2023 | 35,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Mar 31, 2023 | 134,000.00 |
| Mar 31, 2023 | 134,000.00 |